Description
Erdafitinib Tablets 4 mg contain Erdafitinib 4 mg, an oral targeted anticancer medicine that belongs to the Fibroblast Growth Factor Receptor (FGFR) inhibitor class. It is prescribed for eligible adults with certain cancers that have susceptible FGFR2 or FGFR3 genetic alterations, as confirmed by an appropriate diagnostic test.
Erdafitinib works by blocking abnormal FGFR proteins that promote the growth and survival of cancer cells. By inhibiting these proteins, the medicine may help slow or stop tumor growth in eligible patients.
Treatment with Erdafitinib should be initiated and monitored by an oncologist experienced in the use of targeted cancer therapies. Patients typically require regular monitoring, including blood phosphate levels and periodic eye examinations during treatment.
Key Features
- Contains Erdafitinib 4 mg
- Oral targeted anticancer therapy
- FGFR (Fibroblast Growth Factor Receptor) inhibitor
- Used in eligible patients with specific FGFR gene alterations
- Requires regular medical monitoring during treatment
Uses
Erdafitinib Tablets 4 mg may be prescribed for:
- Eligible adults with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 genetic alterations, according to the approved indication in the country of use.
How It Works
Erdafitinib selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4 proteins. Blocking these receptors helps reduce abnormal cell signaling that can drive the growth and spread of cancers with FGFR alterations.
Additional information
| Pack Size | 1 Bottle, 2 Bottles, 3 Bottles, 4 Bottles |
|---|
